On October 2, 2024, Cari Gallman, EVP of Corporate Affairs at Bristol-Myers Squibb (BMY), completed a stock transaction involving the company's common stock. Gallman exercised options to acquire 4,558 shares at no cost, as indicated by a transaction code of 'M', which represents the exercise or conversion of derivative security. Subsequently, Gallman sold 1,648 shares at a price of $53.76 per share, under the transaction code 'F', typically used for the payment of exercise price or tax liability by delivering or withholding securities. After these transactions, Gallman's direct holdings in Bristol-Myers Squibb common stock amounted to 5,019 shares. The total market value of the disposed shares was calculated at $88,596.48.

On October 2, 2024, Cari Gallman, EVP of Corporate Affairs at Bristol-Myers Squibb (BMY), completed a stock transaction involving the company's common stock. Gallman exercised options to acquire 4,558 shares at no cost, as indicated by a transaction code of 'M', which represents the exercise or conversion of derivative security. Subsequently, Gallman sold 1,648 shares at a price of $53.76 per share, under the transaction code 'F', typically used for the payment of exercise price or tax liability by delivering or withholding securities. After these transactions, Gallman's direct holdings in Bristol-Myers Squibb common stock amounted to 5,019 shares. The total market value of the disposed shares was calculated at $88,596.48.